Check before giving

Anaphylaxis requires epinephrine; albuterol is an adjunct for bronchospasm.
If pediatric respiratory status worsens or treatment fails, contact base; a pediatric-capable base is preferred.

Use in OCEMS

Used for wheezing/bronchospasm, including asthma or COPD, and selected smoke-inhalation and crush-injury pathways.
Persistent severe bronchospasm may require additional base-directed treatment; bronchodilator delivery does not replace ventilatory support.

Indication / route	Dose & limits
Nebulized solution	5 mg in 6 mL by continuous nebulization, as tolerated, under the relevant standing order.
Metered-dose inhaler listed in I-15	90 mcg per actuation: 2 puffs every 2 hours until symptoms resolve. Check that the applicable MDI procedure and agency authorization apply.

SO-P-035 specifies 5 mg in 6 mL by continuous nebulization for wheezing/suspected asthma. SO-P-060 also uses this regimen for anaphylaxis with wheeze or hypoxia.
I-20 lists 2.5 mg in the 3–5 kg newborn band. This differs from the general pediatric respiratory standing-order wording: reconcile the neonatal dose with base rather than treating the table and condition order as interchangeable.

SO-P-035 / SO-P-060: continuous nebulization for the specified wheezing/respiratory indication. Weight does not independently establish treatment eligibility.

Weight / use	Pediatric dose	Volume / route
3–5 kg newborn band	Resolve source difference with base	I-20: 2.5 mg / 3 mL; general SO-P-035: 5 mg / 6 mL
Other eligible pediatric patients	5 mg	6 mL by continuous nebulization as tolerated

Nebulizer stock is commonly 2.5 mg/3 mL; confirm the total medication and volume.
Reassess air movement, work of breathing, oxygenation, and heart rate. Consider CPAP only when its separate age and clinical criteria are satisfied.